Endocrine therapy represents the cornerstone of treatment of this tumor subtype, both in the early-stage and in the metastatic setting. All patients with early-stage HR+/HER2- breast cancer are candidates to receive adjuvant endocrine therapy with tamoxifen or aromatase inhibitors. Patients with metastatic HR+/HER2- breast cancer are instead treated with sequence of endocrine-based regimens until the tumor is considered endocrine-sensitive and derive clinical benefit. Endocrine-based regimen typically consist in an endocrine agent (eg, an aromatase inhibitor, a SERD or a SERM) as monotherapy or combined with a targeted agent, such as CDK4/6 inhibitors (eg, palbociclib , abemaciclib, ribociclib), mTOR inhibitors (eg, everolimus), or PIK3CA inhibitors (eg, alpelisib). With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit.
What do you know about HR+/HER2- breast cancer? Test your knowledge with this quick quiz.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan, Stefania Morganti. Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer - Medscape - Jun 28, 2023.